John W. Ward
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John W. Ward has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alex H. Kral
RTI International, San Francisco, California, USA
1 shared publication Bryce D. Smith
Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA
1 shared publication- Claudia Vellozzi
U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
1 shared publication David B. Rein
Univ Chicago, NORC, Chicago, IL 60637 USA
1 shared publication- Hannah Fraser
Population Health Sciences, Bristol Medical School University of Bristol Bristol UK
1 shared publication - Jon Zibbell
RTI International, Research Triangle Park, NC, USA
1 shared publication
Latest Publications
Scaling‐up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic
Background and aims: Effective strategies are needed to address dramatic increases in hepatitis C virus (HCV) infection among people who inject drugs (PWID) in rural settings of the United States. We determined the required scale‐up of HCV treatment with or without scale‐up of HCV prevention interventions to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025 and 2030 in a rural US setting.Design: An ordinary differential equation model of HCV transmission calibrated to HCV epidemiological data obtained primarily from an HIV outbreak investigation in Indiana.Setting: Scott County, Indiana (population 24 181), USA, a rural setting with negligible baseline interventions, increasing HCV epidemic since 2010, and 55.3% chronic HCV prevalence among PWID in 2015.Participants: PWID.Measurements: Required annual HCV treatments per 1000 PWID (and initial annual percentage of infections treated) to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025/30, either with or without scaling‐up syringe service programmes (SSPs) and medication‐assisted treatment (MAT) to 50% coverage. Sensitivity analyses considered whether this impact could be achieved without re‐treatment of re‐infections, and whether greater intervention scale‐up was required due to the increasing epidemic in this setting.Findings: To achieve a 90% reduction in incidence and prevalence by 2030, without MAT and SSP scale‐up, 159 per 1000 PWID (initially 24.9% of infected PWID) need to be HCV‐treated annually. However, with MAT and SSP scaled‐up, treatment rates are halved (89 per 1000 annually or 14.5%). To reach the same target by 2025 with MAT and SSP scaled‐up, 121 per 1000 PWID (19.9%) need treatment annually. These treatment requirements are threefold higher than if the epidemic was stable, and the impact targets are unattainable without retreatment.Conclusions: Combined scale‐up of hepatitis C virus treatment and prevention interventions is needed to decrease the increasing burden of hepatitis C virus incidence and prevalence in rural Indiana, USA, by 90% by 2025/30.
Scaling‐up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic
Background and aims: Effective strategies are needed to address dramatic increases in hepatitis C virus (HCV) infection among people who inject drugs (PWID) in rural settings of the United States. We determined the required scale‐up of HCV treatment with or without scale‐up of HCV prevention interventions to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025 and 2030 in a rural US setting.Design: An ordinary differential equation model of HCV transmission calibrated to HCV epidemiological data obtained primarily from an HIV outbreak investigation in Indiana.Setting: Scott County, Indiana (population 24 181), USA, a rural setting with negligible baseline interventions, increasing HCV epidemic since 2010, and 55.3% chronic HCV prevalence among PWID in 2015.Participants: PWID.Measurements: Required annual HCV treatments per 1000 PWID (and initial annual percentage of infections treated) to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025/30, either with or without scaling‐up syringe service programmes (SSPs) and medication‐assisted treatment (MAT) to 50% coverage. Sensitivity analyses considered whether this impact could be achieved without re‐treatment of re‐infections, and whether greater intervention scale‐up was required due to the increasing epidemic in this setting.Findings: To achieve a 90% reduction in incidence and prevalence by 2030, without MAT and SSP scale‐up, 159 per 1000 PWID (initially 24.9% of infected PWID) need to be HCV‐treated annually. However, with MAT and SSP scaled‐up, treatment rates are halved (89 per 1000 annually or 14.5%). To reach the same target by 2025 with MAT and SSP scaled‐up, 121 per 1000 PWID (19.9%) need treatment annually. These treatment requirements are threefold higher than if the epidemic was stable, and the impact targets are unattainable without retreatment.Conclusions: Combined scale‐up of hepatitis C virus treatment and prevention interventions is needed to decrease the increasing burden of hepatitis C virus incidence and prevalence in rural Indiana, USA, by 90% by 2025/30.
- Open Access
- 18 August 2014
- Published by Wolters Kluwer Health in Hepatology
- Vol. 60 (5) , 1479-1482
Hepatitis C virus: The 25-year journey from discovery to cure
- 18 August 2014
- Published by Wolters Kluwer Health in Hepatology
- Vol. 60 (5) , 1479-1482
Open AccessHepatitis C virus: The 25-year journey from discovery to cure
- 1 February 2013
- Published by Elsevier in Clinics in Liver Disease
- Vol. 17 (1) , 1-11
The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States
- 1 February 2013
- Published by Elsevier in Clinics in Liver Disease
- Vol. 17 (1) , 1-11
The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States
- 1 January 2013
- Published by SAGE Publications in Antiviral Therapy
- Vol. 18 (1) , 139
Testing for HCV: The First Step in Preventing Disease Transmission and Improving Health Outcomes for HCV-Infected Individuals
The author would like to report an error that appeared under the section Need for new US testing strategies in a recently published article [1]. The sentence ‘Compared with pegylated interferon/ribavirin therapy alone, the addition of telaprevir or boceprevir to the treatment regimen has increased the potential for viral clearance from 38% to 63% and 46% to 79%, respectively [26,27], improving health outcomes for individuals living with HCV infection and preventing ongoing disease transmission’ should appear as ‘Compared with pegylated interferon/ribavirin therapy alone, the addition of boceprevir or telaprevir to the treatment regimen has increased the potential for viral clearance from 38% to 63% and 46% to 79%, respectively [26,27], improving health outcomes for individuals living with HCV infection and preventing ongoing disease transmission’. The author apologizes for this error.
- 1 January 2013
- Published by SAGE Publications in Antiviral Therapy
- Vol. 18 (1) , 139
Testing for HCV: The First Step in Preventing Disease Transmission and Improving Health Outcomes for HCV-Infected Individuals
The author would like to report an error that appeared under the section Need for new US testing strategies in a recently published article [1]. The sentence ‘Compared with pegylated interferon/ribavirin therapy alone, the addition of telaprevir or boceprevir to the treatment regimen has increased the potential for viral clearance from 38% to 63% and 46% to 79%, respectively [26,27], improving health outcomes for individuals living with HCV infection and preventing ongoing disease transmission’ should appear as ‘Compared with pegylated interferon/ribavirin therapy alone, the addition of boceprevir or telaprevir to the treatment regimen has increased the potential for viral clearance from 38% to 63% and 46% to 79%, respectively [26,27], improving health outcomes for individuals living with HCV infection and preventing ongoing disease transmission’. The author apologizes for this error.
- 1 October 2012
- Published by Elsevier in Gastroenterology
- Vol. 143 (4) , 887-889
Data to Guide the “Test and Treat Era” of Hepatitis C
- 1 October 2012
- Published by Elsevier in Gastroenterology
- Vol. 143 (4) , 887-889
Data to Guide the “Test and Treat Era” of Hepatitis C
- Open Access
- 24 April 2012
- Published by Wolters Kluwer Health in Hepatology
- Vol. 56 (2) , 419-421
Hepatitis B in the United States: A major health disparity affecting many foreign-born populations
- 24 April 2012
- Published by Wolters Kluwer Health in Hepatology
- Vol. 56 (2) , 419-421
Open AccessHepatitis B in the United States: A major health disparity affecting many foreign-born populations
- 1 January 2012
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (7 Pt B) , 1397-1401
Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals
In the US, application of antibody-based and nucleic acid testing for HCV has dramatically reduced HCV transmissions over the past two decades. In addition to testing donors of blood, tissue and organs to reduce the risk of transfusion/transplantation-associated HCV, testing can also motivate individuals to adopt safer behaviours. HCV testing, when accompanied by appropriate care and treatment, can reduce the extent of morbidity and mortality that often accompanies chronic HCV infection. Options for HCV treatment have recently been expanded and improved with the availability of more effective, anti-HCV drugs; furthermore, the remarkable results of clinical trials of these drugs suggest that safe, all-oral therapies requiring relatively short duration are on the immediate horizon. These advances have prompted new US initiatives to recommend HCV testing to the wider community (including those populations with a high prevalence of hepatitis C) and promote linkage to treatment for those found to be HCV-infected. Crucial to the success of these initiatives are the development of tests capable of identifying active infection, recent infection, or both, and the implementation of testing strategies that facilitate broad access to HCV testing linked to care and treatment.
- 1 January 2012
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (7 Pt B) , 1397-1401
Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals
In the US, application of antibody-based and nucleic acid testing for HCV has dramatically reduced HCV transmissions over the past two decades. In addition to testing donors of blood, tissue and organs to reduce the risk of transfusion/transplantation-associated HCV, testing can also motivate individuals to adopt safer behaviours. HCV testing, when accompanied by appropriate care and treatment, can reduce the extent of morbidity and mortality that often accompanies chronic HCV infection. Options for HCV treatment have recently been expanded and improved with the availability of more effective, anti-HCV drugs; furthermore, the remarkable results of clinical trials of these drugs suggest that safe, all-oral therapies requiring relatively short duration are on the immediate horizon. These advances have prompted new US initiatives to recommend HCV testing to the wider community (including those populations with a high prevalence of hepatitis C) and promote linkage to treatment for those found to be HCV-infected. Crucial to the success of these initiatives are the development of tests capable of identifying active infection, recent infection, or both, and the implementation of testing strategies that facilitate broad access to HCV testing linked to care and treatment.
- Open Access
- 1 May 2008
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 14 (5) , 866a-866
Twelve Diseases That Changed Our World
- 1 May 2008
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 14 (5) , 866a-866
Open AccessTwelve Diseases That Changed Our World